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http:WHAT THIS PAPER ADDS
The BOA Risk Chart 2 predicts mortality and ischemic events after peripheral bypass surgery.Objectives: A prediction model to identify determinants and quantify the risk of future ischaemic events in
patients with peripheral arterial disease (PAD) provides a personal risk proﬁle to offer individualized patient care.
A risk chart was derived and validated in patients who received infrainguinal bypass surgery.
Methods: The Bypass Oral anticoagulants or Aspirin Risk Chart (BOA-RC2) was based on a pre-deﬁned subgroup
of the Dutch BOA trial (N ¼ 482), the derivation cohort. The primary outcome event for BOA-RC2 was the
composite of all cause death, non-fatal myocardial infarction, or non-fatal ischaemic stroke during a 10 year
follow up. Determinants and long-term risk were identiﬁed with multivariate Cox regression analyses. Validation
of the BOA-RC2 was performed in the remaining patients of the complete BOA trial cohort
(N ¼ 2,650  482 ¼ 2,168), the validation cohort.
Results: The primary outcome event occurred in 67% (321/454) of the derivation cohort and in 66% (1,371/
2,083) of the validation cohort during a median follow up of 6.6 years. The BOA-RC2 included the following
determinants: age, critical limb ischaemia, diabetes, and a prior vascular intervention. The performance of the
BOA-RC2 was good with a Brier score of 0.19, an area under the curve of 0.73, and a HosmereLemeshow statistic
of p ¼ .9.
Conclusions: The BOA-RC2 proves to be ﬁt for the prediction of mortality and major ischaemic events in patients
after peripheral bypass surgery. The BOA-RC2 can be used to adequately inform the patient about his/her risk of
future events in an illustrative manner and stress the necessity of preventative measures, such as lifestyle
adjustments, screening for risk factors, and drug treatments. In the future, the BOA-RC2 may be of interest to
identify patients at high risk of mortality and ischaemic events for clinical research on new therapeutic options.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Infrainguinal bypass surgery is a commonly accepted
treatment for critical limb ischaemia, a grave manifestation
of peripheral arterial disease (PAD).1 Compared with pa-
tients with coronary artery disease or cerebrovascular dis-
ease, patients with PAD have the highest risk of vascular
death and the second highest risk of myocardial infarction
and stroke.2,3
Personal risk proﬁles might help the physician to offer
individualized patient care and improve clinical decision
making for optimal secondary prevention. To this end, arresponding author. Department of Vascular Surgery, G04.129, UMC
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//dx.doi.org/10.1016/j.ejvs.2015.04.005prediction model was derived in 2009 to identify de-
terminants and quantify the long-term risk of future
ischaemic events in patients with PAD.4 This initial model,
the BOA Risk Chart (BOA-RC1), was based on a subset of
participants of the Dutch Bypass Oral anticoagulants or
Aspirin (BOA) trial, who received infrainguinal bypass sur-
gery.5 The primary outcome event of the BOA-RC1 was the
composite of vascular death, non-fatal myocardial infarc-
tion, non-fatal ischaemic stroke, or major lower limb
amputation.
In the present study, the aim was to further improve the
chart’s clinical and socialeeconomical usefulness by ﬁrst
adjusting the primary outcome event and, second, vali-
dating this adjusted BOA Risk Chart (BOA-RC2). The primary
outcome event now includes death by all causes instead of
death by a vascular cause alone. Validation of the BOA-RC2
makes the model ready for external use. In addition, de-
rivative charts of the BOA-RC2 were developed to show the
risk at different time intervals (2, 5, and 10 years) in
88 P.P. Wisman et al.combination with a chart displaying the observed median
time to event per risk category in the validation cohort,
which makes the model more informative through time.METHODS
Derivation cohort
The BOA-RC1 and BOA-RC2 were based on a predeﬁned
subgroup of patients from the Dutch BOA trial, referred to
as the derivation cohort. Full details of the Dutch BOA trial
and derivation of the BOA-RC1 have been published else-
where.4,5 In summary, the Dutch BOA trial included 2,650
patients after infrainguinal bypass surgery from 77 medical
centres throughout the Netherlands between 1995 and
1998. Patients were randomly allocated to receive oral
anticoagulation or aspirin to study the effects of oral anti-
coagulants and aspirin in preventing bypass occlusion,
lower limb amputation, and ischaemic events.
The derivation cohort consisted of 482 patients (18%)
from the Dutch BOA trial. These patients were included by
six of the 77 participating medical centres that had been
selected because they contributed a large proportion of
patients in the Dutch BOA trial. The follow up data of these
482 patients were extended from 1998 to 2009 and
collected from the vascular surgeon, general practitioner,
patient, or relatives and acquaintances in a stepwise
manner according the proven effective method of the LiLAC
Study.6
The primary outcome event of the BOA-RC1 was the
composite of vascular death, non-fatal myocardial infarc-
tion, non-fatal ischaemic stroke, or major lower limb
amputation. Determinants of the primary outcome event
were age, critical limb ischaemia, diabetes, and a prior
vascular intervention.
To further optimize the clinical and socialeeconomical
usefulness of the BOA-RC1, it was decided to adjust the
primary outcome event by substituting vascular mortality
for all-cause mortality. Also, follow up data on lower limb
amputation were not available in the National Registry of
Hospital Discharge Diagnoses and were omitted from the
adjusted primary outcome event. So, the adjusted primary
outcome event for the BOA-RC2 was the composite of all
cause death, non-fatal myocardial infarction, and non-fatal
ischaemic stroke (whichever occurred ﬁrst). Adjudication
and classiﬁcation of the outcome events has been described
previously.4 Brieﬂy, a panel consisting of a vascular surgeon,
a clinical epidemiologist, a neurologist, and a cardiologist
adjudicated and classiﬁed the outcome events according to
the pre-speciﬁed deﬁnitions (Supplementary Table 1).Validation cohort
To BOA-RC2 was validated in the remaining patients of the
complete cohort of the Dutch BOA trial
(N ¼ 2,650  482 ¼ 2,168), referred to as the validation
cohort. The long-term follow up data of the validation
cohort were collected at the National Death Registry and
the National Registry of Hospital Discharge Diagnoses fromJanuary 1995 to December 2007, using a validated proba-
bilistic method.7e9 In these databases, cause of death and
the indications for hospitalization are coded according to
the International Classiﬁcation of Diseases, Ninth Revision
(ICD-9).10 Events used for the composite outcome event
were all cause mortality, myocardial infarction (ICD-9 codes
410), and ischaemic cerebrovascular accidents (ICD-9 codes
433e434). The main diagnoses per code are displayed in
Supplementary Table 2. Major limb amputation was not
available in the National Registry of Hospital Discharge Di-
agnoses. This study was conducted in accordance to the
Declaration of Helsinki and procedures were approved by
the institutional review board of the UMC Utrecht. All pa-
tients gave written informed consent.
Statistical analyses
Continuous variables were summarized as means, and
discrete variables were summarized as frequencies and
percentages. Missing ankleebrachial index (ABI) data of 81
patients in the derivation cohort were imputed with mul-
tiple imputations. The cumulative risk of mortality and
vascular events with 95% conﬁdence intervals (CI) was
estimated with KaplaneMeier analysis and presented
graphically as KaplaneMeier curves. Differences between
the derivation and validation cohort were analysed with the
Student t test.
Derivation BOA-RC2
Derivation of the BOA-RC2 was performed in the previously
described derivation cohort (N ¼ 482) similarly to the BOA-
RC1 derivation that has been described elsewhere.4 In brief,
risk factor assessment was performed with the Cox pro-
portional hazards model and associated variables that
yielded p <.20 in the univariate analysis were included in
the multivariate analysis. Independent predictors of the
primary outcome event (p <.05) were identiﬁed using
backward stepwise elimination. The regression coefﬁcients
of the independent predictors were reduced with a uniform
shrinkage factor.11 Discriminatory performance of the
model was assessed with area under receiver operator
characteristic curves (AUC-ROC). In addition to the model
derived from all patients in the derivation cohort, separate
models for patients with critical limb ischaemia and inter-
mittent claudication were compared.
The BOA-RC2 was developed based on all the indepen-
dent predictors from the Cox proportional hazards model
with the highest AUC-ROC and displayed the 10 year risks
for the primary outcome event in patients with any com-
bination of these predictors.
Derivative charts displaying 2 and 5 year risks for the
primary outcome event were developed based on the
model used for the BOA-RC2.
Validation BOA-RC2
The overall performance of the BOA-RC2 in the validation
cohort was assessed by calculating the Brier score.12 The
discriminatory performance was assessed by calculating the
Risk Chart for Future Mortality and Ischaemic Events 89area under the ROC curve and its calibration was analysed
by a calibration graph and the HosmereLemeshow test.13 In
addition, a chart displaying the observed median time to
event per risk category in the validation cohort was made.
The validation analyses were done in SPSS version 14.0 and
graphs were made in GraphPad Prism version 5.03.RESULTS
Derivation cohort
The follow up data of the derivation cohort were complete
in 94% of the 482 patients (N ¼ 454). The median follow up
was 6.6 years. The mean age of the derivation cohort was
69 years (SD 10). The patients’ baseline characteristics are
summarized in Table 1. The primary outcome event
occurred in 66.7% (N ¼ 321) of patients. The primary
outcome event consisted of 242 deaths (50.2%), 44
myocardial infarctions (9.1%), and 35 strokes (7.3%). The
primary outcome event occurred within the ﬁrst 30 days of
peripheral bypass surgery in seven patients (0.2%).Validation cohort
The follow up data of the validation cohort were complete
in 96% of the 2168 patients (N ¼ 2,083). The median followTable 1. Baseline characteristics among patients of the derivation
cohort and the validation cohort.
Baseline
characteristics
Derivation cohort
(N ¼ 482)
Validation cohort
(N ¼ 2083)
Demographic characteristics
Male sex 313 (65%) 1331 (64%)
Age >69 years 274 (57%) 1124 (54%)
Age (mean, SD) 69 (10) 69 (10)
Medical history
Angina pectoris 80 (17%) 346 (17%)
Myocardial
infarction
75 (16%) 374 (18%)
TIA and/or stroke 49 (10%) 247 (12%)
ABI (mean, SD) 0.54 (0.39) 0.55 (0.33)
ABI  0.9 450 (93%) 1560 (94%)
ABI  0.6 288 (60%) 1136 (68%)*
Critical limb
ischaemia
220 (46%) 1039 (50%)
Diabetes mellitus 109 (23%) 569 (27%)*
Hypertension 186 (39%) 815 (39%)
Hyperlipidaemia 101 (21%) 324 (16%)*
Smoking 289 (60%) 1103 (53%)*
Vascular
intervention
213 (44%) 962 (46%)
Trial bypass
Femorocrural/
pedal bypass
107 (22%) 409 (20%)
Venous bypass 313 (65%) 903 (43%)*
Trial medication
Oral anticoagulants 239 (50%) 1043 (50%)
Note. Data are number (%) unless otherwise indicated. SD:
standard deviation; TIA: transient ischaemic attack;
ABI ¼ ankleebrachial index.
*p-Value < .05.up was 6.6 years. The mean age of the validation cohort was
69 years (SD 10). The primary outcome event occurred in
65.8% (N ¼ 1,371) of patients. The event free survival is
shown in Fig. 1. The commonest primary outcome event
was death (53.0%; N ¼ 1,105) followed by myocardial
infarction (7.6%; N ¼ 159) and stroke (5.1%; N ¼ 107).
During the ﬁrst 30 days the primary outcome event
occurred in 35 patients (0.2%).
The patients’ baseline characteristics of the total Dutch
BOA study population and the validation cohort are sum-
marized in Table 1. A larger proportion of patients had an
ABI 0.6 in the validation cohort than the derivation
cohort; the same is true for diabetes mellitus. Fewer pa-
tients had hyperlipidaemia, were smokers, or received a
venous bypass in the validation cohort than the derivation
cohort.BOA-RC2 derivation
Baseline characteristics associated with the primary
outcome event in a univariate model were increasing age,
diabetes, critical limb ischaemia, previous myocardial
infarction, ABI 0.6, hypertension, hyperlipidaemia, previ-
ous vascular intervention and femorocrural or femoropedal
bypass. Besides hyperlipidaemia, all these characteristics
increased the risk of a primary outcome event.
The independent determinants of the primary outcome
event were increasing age, diabetes, critical limb ischaemia,
and a previous vascular intervention. The AUC-ROC curve of
the prediction model for the primary outcome event was
0.78 (95% CI 0.73e0.82) (Table 2). The independent de-
terminants for patients with critical limb ischaemia were
age and diabetes; for patients with intermittent claudication
the independent determinants were age and prior vascular
events. Separate Cox regression models for patients with
critical limb ischaemia and intermittent claudication did notFigure 1. KaplaneMeier curve of the composite primary outcome
event free survival of the validation cohort (N ¼ 2083). Note. y-
axis: percentage of primary outcome event free survival of the
validation cohort; x-axis: Time in years with the number of patients
at risk per year.
Table 2. Indicator variables retained in Cox regression models for prediction of the primary outcome event.
All patients HRa (95% CI) CLI HRa (95% CI) IC HRa (95% CI)
Demographic facts
Ageb 1.06 (1.05e1.07) 1.05 (1.03e1.86) 1.07 (1.04e1.09)
Medical history
Critical limb ischaemia 1.5 (1.2e1.8) e e
Diabetes mellitus 1.4 (1.1e1.7) 1.4 (1.0e1.9) e
Vascular intervention 1.3 (1.1e1.7) e 1.5 (1.1e2.1)
ROC-AUC (95% CI) 0.78 (0.73e0.82) 0.76 (0.69e0.84) 0.75 (0.69e0.81)
CLI ¼ critical limb ischaemia; IC ¼ intermittent claudication; ROC-AUC ¼ area under the receiver operator characteristic curve.
a Hazard ratio (HR) after shrinkage.
b Age was taken as a continuous variable with the HR representing the risk per year increase.
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respectively 0.76, 0.75).
Fig. 2 systematically displays the 10 year predicted risks
of the primary outcome event for each combination of the
four independent determinants. These risks ranged from
28% for a patient younger than 65 years of age with
intermittent claudication, no diabetes, and no prior vascular
intervention to 97% for a patient older than 75 years of age
with critical limb ischaemia, diabetes, and a prior vascular
intervention. Comparable risk distribution was seen in the
derivative charts displaying 2 and 5 year risks for the pri-
mary outcome.BOA-RC2 validation
The overall performance of the BOA-RC2 in the validation
cohort was fair with a Brier score of 0.19. The AUC-ROC
analysis showed a fair to good discriminatory perfor-
mance of the BOA-RC2 in the validation cohort with an area
under the curve of 0.73 (95% CI 0.71e0.75) (Fig. 3). The
BOA-RC2 predicted 1,395 primary outcome events in the
validation cohort, while 1,372 primary outcome events
were observed in the validation cohort. The Hosmere
Lemeshow statistic (chi-square 13.56; p ¼ .9) showed great
goodness of ﬁt between expected and observed primaryFigure 2. The BOA-RC2 with the 10 year risk of the composite prima
predictors and derived charts displaying 2 and 5 year risk. Note. Cut of
85% for 2, 5, and 10 year risk respectively. CLI ¼ critical limb ischaemoutcome events. Furthermore, the calibration curve showed
similar numbers of expected and observed primary
outcome events (Fig. 4), representing a good calibration of
the BOA-RC2. The median time to event ranged from 10
years for young patients with intermittent claudication to 3
years for patients older than 75 years of age with critical
limb ischaemia, diabetes, and a prior vascular intervention
(Fig. 5).DISCUSSION
Patients with PAD, especially critical limb ischaemia, are at
high risk of secondary, usually fatal, ischaemic events.
Therefore individual risk assessment of mortality or major
ischaemic events in patients who require peripheral bypass
surgery is essential to adequately inform the patient and
apply patient speciﬁc preventative measures, such as life-
style adjustments, screening, and drug treatments. Up to
now, long-term data of major ischaemic events in PAD pa-
tients were scarce and even lacking for patients with severe
PAD, preventing an accurate risk assessment of future
ischaemic events. Therefore, all major ischaemic events of
patients from the Dutch BOA trial during a 10 year follow up
were collected. Ten years after peripheral bypass surgery,
66% of the patients had died, suffered a myocardialry outcome event for each combination of the four independent
f points average risk: 10%, 40%, and 60%; high risk: 20%, 40%, and
ia.
Figure 3. Discriminatory performance of the BOA-RC2 in the vali-
dation cohort. Note. Area under the curve: 73%, 95% CI 71e75%.
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RC2 was derived in order to easily assess the individual
long-term risk of mortality or major ischaemic events. The
10 year risks ranged from 28% for a patient younger than 65
years with intermittent claudication, no diabetes, and no
prior vascular intervention up to 97% for a patient older
than 75 years with critical limb ischaemia, diabetes, and a
prior vascular intervention. To further aid clinical decision
making derivative charts displaying the 2 and 5 year risk of
death and major cardiovascular events and a chart dis-
playing the observed median time to event per risk category
in the validation cohort were produced (Figs. 2 and 5). As
far as is known, the BOA-RC2 is the ﬁrst validated risk chart
that quantiﬁes long-term risk of secondary cardiovascular
events or death of patients with severe PAD.
Estimating a patient’s 10 year risk with the BOA-RC2 is
independent of current use of oral anticoagulants or aspirin
and also of the type of bypass graft constructed, as these
determinants did not contribute to the prediction model.Figure 4. Calibration of the BOA-RC2 in the validation cohort. Note.
Intercept of the calibration curve: 0.04. Slope of the calibration
curve: 0.91.Strengths and limitations
In accordance with the trend in current literature and the
preference of health care ﬁnancial management to report
all cause mortality, the composite primary outcome event
of the original BOA Risk Chart (BOA-RC1) was adjusted by
including all cause mortality as opposed to vascular mor-
tality alone. In addition, the outcome event vascular death
has a more speciﬁc deﬁnition than all cause death, leaving
more room for misinterpretation and subsequent erroneous
coding. The straightforward outcome event all cause death
is clear and more suitable for broad use.
Furthermore, the BOA-RC2 was derived from a popula-
tion consisting of both patients with critical limb ischaemia
and patients with severe claudication. Though patients at an
advanced stage of PAD are at a higher risk of ischaemic
events, separate Cox regression models for patients with
critical limb ischaemia and claudication did not show a
higher discriminatory performance (ROC-AUC, respectively
0.76, 0.75) than the BOA-RC2 (ROC-AUC 0.78). The lack of
improvement in discriminatory power of the separate
models is most likely caused by the fact that both
researched stages of severe PAD share the same risk factors
for future mortality and cardiovascular events. The BOA-RC2
showed a good calibration and discriminatory performance
in the validation cohort. This emphasizes that the BOA-RC2
gives an accurate risk assessment and is appropriate for
external use.
Unfortunately, follow up data on lower limb amputations,
an important adverse event in patients with PAD, were
missing and not included in the composite primary outcome
event of the BOA-RC2. In the derivation cohort only 3% of
the patients had a major amputation during 10 year follow
up in addition to the 67% of patients that died, suffered a
myocardial infarction, or an ischaemic stroke. Therefore, it is
believed that this model would not dramatically improve
with a primary outcome event that included major ampu-
tation. Further data on amputation risk can be found in
previous manuscripts from the BOA study group.4,5
The determinants of the composite primary outcome
event, such as a history of vascular intervention, most of
which were performed in the legs, and critical limb
ischaemia, are very speciﬁc for PAD and not just for
atherosclerosis in general, such as age and diabetes.
Therefore, it is believed that the BOA-RC2 remains exclu-
sively for patients with PAD after peripheral bypass surgery
despite excluding major limb amputations from the primary
outcome event.
Furthermore, the larger part of the data in the derivation
cohort was collected retrospectively, except for the ﬁrst 2
years between 1995 and 1998, which were performed
prospectively. To reduce the number of missed events to a
minimum, the follow up data from 1998 to 2009 were
collected in a step wise manner. It is believed that this
method has proven to be effective, as the number of events
recorded in the derivation cohort was very similar to the
number of events recorded in the validation cohort by na-
tional registries. The long-term follow up data of the
Figure 5. Observed median time to event for each combination of the four independent predictors of the patients in the validation cohort.
CLI ¼ critical limb ischaemia.
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registries were nearly complete (96%).
Differences in patient characteristics such as ABI 0.6,
diabetes, hyperlipidaemia, smoking, and venous bypass
between the derivation and validation cohort were
observed. These differences included one independent
determinant incorporated in the BOA-RC2 (diabetes), but
did not result in a difference in risk of the primary outcome
event between the cohorts. Therefore, no calibration
adjustment of the BOA-RC2 was required, which was
conﬁrmed by the results of the validation.
Undoubtedly, the application of secondary prevention
management has improved (e.g. increased use of statins
and platelet aggregation inhibition) since the onset of the
BOA trial in 1995, reducing the risk of ischaemic events.
Unfortunately, data on these changes in baseline medical
history could not be collected, but the follow up data on
ischaemic events were extended up to December 2007,
with only a small percentage of missing events. In theory,
these changes would reduce the BOA-RC2 calibration for
the current patient, but should not affect its discriminatory
performance.
For adequate risk estimation in a similar population, such
as patients with PAD following endovascular interventions,
validation studies of the BOA-RC2 in these populations are
recommended. Furthermore, adjustment of the BOA-RC2
based on the setting of similar populations can improve
the performance of the risk chart.14CONCLUSION
The BOA-RC2 proves to be ﬁt for the prediction of mortality
and major ischaemic events in patients after peripheral
bypass surgery. The BOA-RC2 can be applied to adequately
inform the patient of his/her risk of future events in anillustrative manner and stress the necessity of preventative
measures, such as lifestyle adjustments (e.g. physical exer-
cise, smoking cessation), screening for risk factors (e.g.
HbA1c and cholesterol levels; cardiac and cerebrovascular
evaluation), and drug treatments (statins, antiplatelet
therapy and blood pressure regulation). In the future, the
BOA-RC2 may be of interest to identify patients at high risk
of mortality and ischaemic events for clinical research on
new therapeutic options.
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